Key result
The optimized HeartAssist 5 VAD demonstrated an order of magnitude lower platelet activation rate compared to the original DeBakey VAD (3x10^-5 vs 3x10^-4 min^-1, p<0.01) in an in vitro flow loop.
Why the study?
Does the optimized HeartAssist 5 LVAD reduce in vitro platelet activation and stress accumulation compared to the original DeBakey VAD?
Population
In silico numerical simulations and in vitro circulation flow loops using bovine blood and human purified…
Comparison
Optimized rotary Left Ventricular Assist Device vs Original rotary Left Ventricular Assist Device
Design
Preclinical
Follow-up
30 min
Authors
Loading...
Should not yet alter LVAD selection or antithrombotic regimens; extends in vitro optimization methods for future device development.
Does the optimized HeartAssist 5 LVAD reduce in vitro platelet activation and stress accumulation compared to the original DeBakey VAD?
Effect estimate: an order of magnitude lower
Absolute Event Rate: 0.00003% vs 0.0003%
p-value: p=<0.01
The Device Thrombogenicity Emulation methodology successfully optimized an LVAD design, resulting in an order of magnitude reduction in in vitro platelet activation, which may translate to a reduced need for complex antithrombotic therapy in clinical use.
Girdhar et al. (2012) studied Mechanical circulatory support device thromboresistance (n=10). HeartAssist 5 (Optimized VAD design) vs. DeBakey VAD (Original VAD design) was evaluated on Platelet Activity Rate (PAR) measured in a flow-loop (an order of magnitude lower, p=<0.01). The optimized HeartAssist 5 VAD demonstrated an order of magnitude lower platelet activation rate compared to the original DeBakey VAD (3x10^-5 vs 3x10^-4 min^-1, p<0.01) in an in vitro flow loop.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: